Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.
Efficacy and Safety of Tamsulosin, a Selective Alpha-1 Adrenergic Blocker, for Children with Posterior Urethral Valve: a Randomized Controlled Trial
Mansoura University
50 participants
Nov 1, 2024
INTERVENTIONAL
Conditions
Summary
To determine whether there is a role for Tamsulosin, A Selective Alpha-1 Adrenergic Blocker, as therapy in children with Posterior Urethral Valve post valve ablation , and whether there are side effects involved.
Eligibility
Inclusion Criteria1
- Children with a diagnosis of PUV.
Exclusion Criteria5
- Patients with other conditions that can potentially affect lower or upper urinary tract functions (e.g. spinal dysraphism, anorectal malformation and prune belly syndrome)
- Patients who were treated with urinary diversion as vesicostomy or cutaneous ureterostomy.
- Patients who had primary treatment of PUV ablation at other hospitals.
- Contraindications to α blocker treatment.
- Patients who refuse to participate in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Children will be maintained on an oral dose of Tamsulosin 0.1 mg once daily (in children aged less than 2 years old) and 0.2 mg once daily (≥2 years old).
Children will be maintained on an oral dose of Oxybutynin 0.2 mg/kg 2 times daily.
Children will be maintained on an oral prophylactic dose of Trimethoprim/sulfamethoxazole 2 mg/kg single dose at night.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06737016